Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARSB siRNA
- Development stage
- Preclinical
- Lead developer
- University of Illinois Chicago
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
ARSB siRNA is a small interfering RNA (siRNA) designed to silence the expression of the enzyme arylsulfatase B (ARSB), also known as N-acetylgalactosamine 4-sulfatase. ARSB is a lysosomal enzyme responsible for the degradation of sulfated glycosaminoglycans, specifically by removing 4-sulfate groups from N-acetylgalactosamine 4-sulfate residues in chondroitin 4-sulfate (C4S) and dermatan sulfate (DS). In research contexts, particularly in melanoma, silencing ARSB leads to an accumulation of highly sulfated C4S, which triggers transcriptional pathways involving galectin-3, AP-1, and Sp1. This results in the upregulation of chondroitin sulfate proteoglycan 4 (CSPG4) and increased matrix metalloproteinase (MMP) activity, thereby enhancing the invasive potential of melanoma cells. It is primarily utilized as a laboratory tool to investigate the role of ARSB in cancer progression and glycosaminoglycan metabolism.
- Other names
- arylsulfatase B siRNAN-acetylgalactosamine 4-sulfatase siRNAN-acetylgalactosamine4-sulfatase siRNAN-acetylgalactosamine-4-sulfatase siRNA
02
Targets
ARSB (N-acetylgalactosamine 4-sulfatase)
Beyond the preview
Go deeper on ARSB siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARSB siRNA.